CorMedix (CRMD) Surpasses Q1 Earnings and Revenue Estimates

Financial Performance - CorMedix reported quarterly earnings of $0.30 per share, exceeding the Zacks Consensus Estimate of$0.25 per share, compared to a loss of $0.25 per share a year ago, representing an earnings surprise of 20$39.08 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 8.76%, compared to zero revenues a year ago [2] Stock Performance - CorMedix shares have increased approximately 11.5% since the beginning of the year, while the S&P 500 has declined by 3.9% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.10 on revenues of$26.31 million, and for the current fiscal year, it is $0.72 on revenues of$132.38 million [7] - The estimate revisions trend for CorMedix is mixed, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which CorMedix belongs, is currently in the top 31% of over 250 Zacks industries, suggesting that stocks in the top 50% outperform those in the bottom 50% by more than 2 to 1 [8]